Dr. Jack Cush reviews the news, reports, pipeline and drug repurposing on this week’s podcast.
Dr. John Cush RheumNow
1 year ago
2025 BSR Recommendations for ANCA-associated Vasculitis
The BSR and BHPR have published a guideline for the management of adults with AAV; specifically three conditions: GPA, MPA, and EGPA.
https://t.co/nYpbBK7Ahr https://t.co/J4KcAzA5Xd
Researchers from the University of Pennsylvania have published an open-access review of dermatomyositis (DM) - its manifestations, hallmark cutaneous features, etiopathogenesis and treatment options.
The Journal of Rheumatology has published an analysis of antinuclear antibody (ANA) multiplex testing showing its nonspecific utility and poor rate of return in identifying ANA-associated autoimmune rheumatic disease (ARDs).
Dr. John Cush RheumNow
1 year ago
Retrospective study of FDG-PET scans at Int. Medicine tertiary hosp (2015-2020), included 260 adult IM pts - indications: infx 42%, inflammation 35%, suspected CA 17%. 80% were helpful; 40% Rx changed. 23% neg. results; 9% made the Dx; 43% PET superior to other imaging. Less https://t.co/2UG2npJgRg
Dr. John Cush RheumNow
1 year ago
Retrospective study of 63 pts w/ Cryoglobulinemia (essential mixed [EM], CTD-related) vasculitis (CryoVas) in remission post RTX induction. W/ 58 mos F/U Relapse rates were 23%, 42%, 71% (@ 1yr, 2yrs, 5yrs). Relapse risk w/ purpura [HR 2.2] & prior CryoVas flare (HR 1.9). https://t.co/6zGgSN8Wfe
Dr. John Cush RheumNow
1 year ago
Rheums Speak - RA Treatment Survey
RheumNow's August 2025 “Live Vote” surveys will examine Rheumatologist impressions, knowledge and practices over the last 20 years when treating rheumatoid arthritis.
https://t.co/hJSQ5mMJ6b https://t.co/466wOjTSGS
Dr. John Cush RheumNow
1 year ago
COVID Vaccine study in rheum pts on JAKi (n 22) or TNFi (n 16) Showing 50% response in JAKi and 81% w/ TNFi Rx. Pt PBMCs were stim by SAR-CoV2 spike proteins & CD4+ T cells IFNγ production as Pos. response. Do JAKi impair COVID-19 Vax responses? https://t.co/dZAktwrytf https://t.co/mjkBfcGcfD
Detailed analysis of the Global Burden of Disease (GBD) 2021 database shows that tobacco and smoking is one of the most significant environmental risk factors for Rheumatoid Arthritis (RA) over the last 20 years.
Rheumatoid arthritis is a common autoimmune disease, and approximately 30%-40% of patients develop pulmonary complications such as idiopathic pulmonary fibrosis (IPF), but the causal relationship between the two has long been unclear.
Dr. John Cush RheumNow
1 year ago
Full read overview of Immune Checkpoint Inhibitors and their downside - immune related Adverse Events https://t.co/h1AzFaGVMz https://t.co/s75UdhE1HK
Dr. John Cush RheumNow
1 year ago
Survey of 39 Spanish rheumatologists (mean age 50 yrs, 9.6 yrs in practice) finds that while 79% agreed on the importance of using Patient-Reported Outcome Measures (PROMs), only 28% use them routinely (mostly pain, VAS, HAQ) - reason? Time! https://t.co/YnZBXlK24M https://t.co/a8W52XO8jh
Dr. John Cush RheumNow
1 year ago
Japans IORRA study of 10,613 RA pts (2007-21) - 915 deaths from cancer (28%), lung Dz (22%), CV Dz (16%). Protective Rx were MTX and bDMARDs, while even low-dose glucocorticoids showed increased mortality risk. https://t.co/lV5WmC5l1X https://t.co/QncyqXSRE9
Dr. John Cush RheumNow
1 year ago
AMN Healthcare report on MD salaries -- high demand for specialist MDs w/ RHEUM the 7th Most In-Demand. 2024/205 Rheum were low of $214K, a high of $450K, median of $341,000. Avg salary for NPs is $180K up from $164,000 last year, a 9.6% increase. https://t.co/NcmwrMxpKr https://t.co/a86NvQhZry
